SMDAM
MRNA icon

Sumitomo Mitsui DS Asset Management’s Moderna MRNA Stock Holding History

Sumitomo Mitsui DS Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$836K Buy
11,938
+1,415
+13% +$73.2K 0.01% 643
2026
Q1 		$535K Buy
10,523
+1,592
+18% +$74.3K ﹤0.01% 665
2025
Q4 		$263K Hold
8,931
– – ﹤0.01% 722
2025
Q3 		$231K Hold
8,931
– – ﹤0.01% 730
2025
Q2 		$246K Sell
8,931
-26,032
-74% -$686K ﹤0.01% 716
2025
Q1 		$991K Buy
34,963
+100
+0.3% +$3.55K 0.01% 627
2024
Q4 		$1.45M Buy
34,863
+657
+2% +$31.4K 0.01% 557
2024
Q3 		$2.29M Buy
34,206
+746
+2% +$68.5K 0.02% 443
2024
Q2 		$3.97M Buy
33,460
+685
+2% +$86.7K 0.05% 299
2024
Q1 		$3.49M Buy
32,775
+3,806
+13% +$384K 0.04% 328
2023
Q4 		$2.88M Buy
28,969
+306
+1% +$25.7K 0.04% 376
2023
Q3 		$2.96M Buy
28,663
+279
+1% +$31.1K 0.05% 314
2023
Q2 		$3.45M Buy
28,384
+2,042
+8% +$272K 0.05% 285
2023
Q1 		$4.05M Buy
26,342
+293
+1% +$48.3K 0.07% 223
2022
Q4 		$4.68M Buy
26,049
+1,489
+6% +$243K 0.09% 179
2022
Q3 		$2.9M Buy
24,560
+1,365
+6% +$207K 0.07% 245
2022
Q2 		$3.31M Buy
23,195
+794
+4% +$113K 0.08% 213
2022
Q1 		$3.86M Buy
22,401
+43
+0.2% +$7.24K 0.08% 206
2021
Q4 		$5.68M Buy
22,358
+76
+0.3% +$22.2K 0.12% 156
2021
Q3 		$8.57M Buy
22,282
+3,418
+18% +$1.26M 0.2% 102
2021
Q2 		$4.43M Buy
18,864
+3,306
+21% +$591K 0.11% 181
2021
Q1 		$2.04M Buy
15,558
+96
+0.6% +$13.9K 0.05% 307
2020
Q4 		$1.61M Sell
15,462
-41
-0.3% -$4.15K 0.05% 343
2020
Q3 		$1.1M Buy
15,503
+12
+0.1% +$837 0.03% 392
2020
Q2 		$994K Buy
+15,491
New +$848K 0.03% 396

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Sumitomo Mitsui DS Asset Management's MRNA Position: Q2 2026 in Review

Sumitomo Mitsui DS Asset Management increased its Moderna (MRNA) stake by 13% in Q2 2026, buying an estimated $73.2K and bringing the position to 11,938 shares worth $836K. The position accounts for 0.01% of the portfolio, ranked #643.

Sumitomo Mitsui DS Asset Management first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $8.57M in Q3 2021. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Sumitomo Mitsui DS Asset Management held 11,938 shares of Moderna worth $836K as of Q2 2026.
  • Sumitomo Mitsui DS Asset Management bought 1,415 Moderna shares in Q2 2026, an estimated $73.2K.
  • Moderna made up 0.01% of Sumitomo Mitsui DS Asset Management's portfolio in Q2 2026, its #643 holding.
  • Sumitomo Mitsui DS Asset Management first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Sumitomo Mitsui DS Asset Management's Moderna position peaked at $8.57M in Q3 2021.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Sumitomo Mitsui DS Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.